Advertisement

Applied DNA Sciences Shares Triples After Monkeypox Diagnostic Test Update

  • Applied DNA Sciences Inc (NASDAQ: APDN) has initiated analytical validation of a company-developed, PCR-based monkeypox virus test specific to the genetic signature of the monkeypox virus.

  • The test has been developed as an NYSDOH Laboratory Developed Test (LDT) type.

  • If Applied DNA validates the test, a validation package will be submitted to the New York State Department of Health (NYSDOH) for approval.

  • If approved, the test will be used to power ADCL's monkeypox testing services.

  • Applied DNA's monkeypox test utilizes an A17L gene-target specific to monkeypox that enables the qualitative detection and differentiation of the monkeypox virus from other non-variola orthopoxviruses using real-time PCR.

  • California Governor Gavin Newsom declared a state of emergency over the monkeypox.

  • California confirmed 827 monkeypox cases, the second-largest state tally after the 1,390 infections documented in New York, according to the U.S. Centers for Disease Control and Prevention.

  • Price Action: APDN shares are up 236.3% at $2.29 during the market session on the last check Tuesday.

See more from Benzinga

ADVERTISEMENT

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.